Literature DB >> 7612873

Ketamine activates psychosis and alters limbic blood flow in schizophrenia.

A C Lahti1, H H Holcomb, D R Medoff, C A Tamminga.   

Abstract

The non-competitive NMDA antagonist ketamine, given to schizophrenic individuals in subanesthetic doses, produced a short-lived, discrete activation of their psychotic symptoms, which had striking similarities to symptoms of their usual psychotic episodes. To further study this psychotomimetic property of ketamine, we administered 0.3 mg kg-1 of the drug to schizophrenic individuals during a [15O] water cerebral blood flow study. Regional cerebral blood flow (rCBF) was measured using H2(15)O and positron emission tomography (PET) before and after ketamine administration to identify regions of flow change, rCBF was increased in anterior cingulate cortex and was reduced in the hippocampus and primary visual cortex (lingual and fusiform gyri). These data encourage further consideration of altered glutamatergic transmission in schizophrenic and PCP-induced psychoses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612873     DOI: 10.1097/00001756-199504190-00011

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  119 in total

1.  Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors.

Authors:  Claude Sebban; Brigitte Tesolin-Decros; Jorge Ciprian-Ollivier; Laurent Perret; Michael Spedding
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 3.  MRI anatomy of schizophrenia.

Authors:  R W McCarley; C G Wible; M Frumin; Y Hirayasu; J J Levitt; I A Fischer; M E Shenton
Journal:  Biol Psychiatry       Date:  1999-05-01       Impact factor: 13.382

Review 4.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 5.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

Review 6.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

7.  Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study.

Authors:  T A Pollak; S De Simoni; B Barimani; F O Zelaya; J M Stone; M A Mehta
Journal:  Psychopharmacology (Berl)       Date:  2015-10-05       Impact factor: 4.530

Review 8.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

9.  Drug discovery in psychiatric illness: mining for gold.

Authors:  Greg I Elmer; Neri Kafkafi
Journal:  Schizophr Bull       Date:  2009-03-18       Impact factor: 9.306

10.  Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors.

Authors:  Ting-Ting Duan; Ji-Wei Tan; Qiang Yuan; Jun Cao; Qi-Xin Zhou; Lin Xu
Journal:  Psychopharmacology (Berl)       Date:  2013-03-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.